Cargando…

Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia

In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindsay, Julian, Kabir, Masrura, Gilroy, Nicole, Dyer, Gemma, Brice, Lisa, Moore, John, Greenwood, Matthew, Hertzberg, Mark, Gottlieb, David, Larsen, Stephen R., Hogg, Megan, Brown, Louisa, Huang, Gillian, Tan, Jeff, Ward, Christopher, Kerridge, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224858/
https://www.ncbi.nlm.nih.gov/pubmed/27790858
http://dx.doi.org/10.1002/cam4.889
_version_ 1782493433474056192
author Lindsay, Julian
Kabir, Masrura
Gilroy, Nicole
Dyer, Gemma
Brice, Lisa
Moore, John
Greenwood, Matthew
Hertzberg, Mark
Gottlieb, David
Larsen, Stephen R.
Hogg, Megan
Brown, Louisa
Huang, Gillian
Tan, Jeff
Ward, Christopher
Kerridge, Ian
author_facet Lindsay, Julian
Kabir, Masrura
Gilroy, Nicole
Dyer, Gemma
Brice, Lisa
Moore, John
Greenwood, Matthew
Hertzberg, Mark
Gottlieb, David
Larsen, Stephen R.
Hogg, Megan
Brown, Louisa
Huang, Gillian
Tan, Jeff
Ward, Christopher
Kerridge, Ian
author_sort Lindsay, Julian
collection PubMed
description In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402‐item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipulative and body‐based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population.
format Online
Article
Text
id pubmed-5224858
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52248582017-01-17 Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia Lindsay, Julian Kabir, Masrura Gilroy, Nicole Dyer, Gemma Brice, Lisa Moore, John Greenwood, Matthew Hertzberg, Mark Gottlieb, David Larsen, Stephen R. Hogg, Megan Brown, Louisa Huang, Gillian Tan, Jeff Ward, Christopher Kerridge, Ian Cancer Med Cancer Prevention In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402‐item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipulative and body‐based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population. John Wiley and Sons Inc. 2016-10-27 /pmc/articles/PMC5224858/ /pubmed/27790858 http://dx.doi.org/10.1002/cam4.889 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Lindsay, Julian
Kabir, Masrura
Gilroy, Nicole
Dyer, Gemma
Brice, Lisa
Moore, John
Greenwood, Matthew
Hertzberg, Mark
Gottlieb, David
Larsen, Stephen R.
Hogg, Megan
Brown, Louisa
Huang, Gillian
Tan, Jeff
Ward, Christopher
Kerridge, Ian
Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title_full Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title_fullStr Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title_full_unstemmed Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title_short Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
title_sort epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in australia
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224858/
https://www.ncbi.nlm.nih.gov/pubmed/27790858
http://dx.doi.org/10.1002/cam4.889
work_keys_str_mv AT lindsayjulian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT kabirmasrura epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT gilroynicole epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT dyergemma epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT bricelisa epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT moorejohn epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT greenwoodmatthew epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT hertzbergmark epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT gottliebdavid epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT larsenstephenr epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT hoggmegan epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT brownlouisa epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT huanggillian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT tanjeff epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT wardchristopher epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia
AT kerridgeian epidemiologyofcomplementaryandalternativemedicinetherapyuseinallogeneichematopoieticstemcelltransplantsurvivorshippatientsinaustralia